Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
32
NCT03454893
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
Phase: Phase 1/2
Role: Lead Sponsor
Start: Feb 21, 2018
Completion: Mar 14, 2022
NCT04999059
Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201
Phase: N/A
Start: May 8, 2019
Completion: Aug 16, 2023
NCT04145037
Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
Start: May 30, 2019
Completion: Aug 21, 2023
NCT04836377
A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02
Start: Jul 6, 2021
NCT05815004
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
Phase: Phase 2/3
Start: Oct 31, 2023
Completion: Dec 31, 2027